Martiniello-Wilks Rosetta, Wang Xiao Yang, Voeks Dale J, Dane Allison, Shaw Jan M, Mortensen Elin, Both Gerald W, Russell Pamela J
Oncology Research Centre, Prince of Wales Hospital Clinical School of Medicine, Faculty of Medicine, The University of New South Wales, Level 2, Clinical Sciences Building, Barker Street, Randwick, NSW 2031, Australia.
J Gene Med. 2004 Dec;6(12):1343-57. doi: 10.1002/jgm.629.
Gene-directed enzyme prodrug therapy based on the E. coli purine nucleoside phosphorylase (PNP) gene produces efficient tumour cell killing. PNP converts adenosine analogs into toxic metabolites that diffuse across cell membranes to kill neighbouring untransduced cells (PNP-GDEPT). Interference with DNA, RNA and protein synthesis kills dividing and non-dividing cells, an important consideration for slow-growing prostate tumours. This study examined the impact of administering PNP-GDEPT into orthotopically grown RM1 prostate cancers (PCas) on the growth of lung pseudo-metastases of immunocompetent mice. C57BL/6 mice bearing orthotopic RM1 PCas received a single intraprostatic injection of OAdV220 (10(10) particles), a recombinant ovine atadenovirus containing the PNP gene controlled by the Rous Sarcoma virus promoter, followed by fludarabine phosphate (approximately 600 mg/m(2)/day) administered intraperitoneally (ip) once daily for 5 days. Pseudo-metastases were induced 2 days after intraprostatic vector administration by tail-vein injection of untransduced RM1 cells. Mice given PNP-GDEPT showed a significant reduction both in prostate volume (approximately 50%) and in lung colony counts (approximately 60%). Apoptosis was increased two-fold in GDEPT-treated prostates compared with controls (P < 0.01), but was absent in the lungs. Staining for proliferating cell nuclear antigen (PCNA) indicated that proliferation of both RM1 prostate tumours (P < 0.01) and lung colonies (P < 0.01) was significantly suppressed after GDEPT. Although prostate tumour immune cell infiltration did not differ significantly between treatments, immunostaining for Thy-1.2 (CD90) showed that GDEPT promoted Thy-1.2(+) cell infiltration into the prostate tumour site. This study showed that a single course of PNP-GDEPT significantly suppressed local PCa growth and reduced lung colony formation in the aggressive RM1 tumour model.
基于大肠杆菌嘌呤核苷磷酸化酶(PNP)基因的基因导向酶前药疗法可有效杀伤肿瘤细胞。PNP将腺苷类似物转化为有毒代谢产物,这些代谢产物可穿过细胞膜杀死邻近未转导的细胞(PNP-GDEPT)。干扰DNA、RNA和蛋白质合成可杀死分裂和不分裂的细胞,这对于生长缓慢的前列腺肿瘤来说是一个重要的考虑因素。本研究考察了将PNP-GDEPT施用于原位生长的RM1前列腺癌(PCa)对免疫活性小鼠肺假转移灶生长的影响。携带原位RM1 PCa的C57BL/6小鼠接受前列腺内单次注射OAdV220(10¹⁰个颗粒),这是一种重组羊腺病毒,含有由劳氏肉瘤病毒启动子控制的PNP基因,随后腹腔注射(ip)磷酸氟达拉滨(约600 mg/m²/天),每天一次,共5天。在前列腺内注射载体2天后,通过尾静脉注射未转导的RM1细胞诱导假转移灶形成。接受PNP-GDEPT治疗的小鼠前列腺体积显著减小(约50%),肺集落计数也显著减少(约60%)。与对照组相比,GDEPT治疗的前列腺中凋亡增加了两倍(P < 0.01),但肺中未出现凋亡。增殖细胞核抗原(PCNA)染色表明,GDEPT后RM1前列腺肿瘤(P < 0.01)和肺集落(P < 0.01)的增殖均受到显著抑制。尽管不同治疗组之间前列腺肿瘤免疫细胞浸润没有显著差异,但Thy-1.2(CD90)免疫染色显示,GDEPT促进了Thy-1.2⁺细胞浸润到前列腺肿瘤部位。本研究表明,在侵袭性RM1肿瘤模型中,单次PNP-GDEPT疗程可显著抑制局部PCa生长并减少肺集落形成。